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Abstract We performed renal biopsy in three cases
complicated by myeloproliferative neoplasms (MPN).
Although several cases of glomerulonephritis associated
with MPN have been reported, the etiologies of the renal
disorders were not established (Plomley et al., Aust NZ J
Med, 13:125–129, 1983; Sharma et al., Nephron, 69:361,
1995; Kanauchi et al., Intern Med, 33:36–40, 1994; Kasuno
et al., Nephrol Dial Transplant, 12:212–215, 1997; Au
et al., Am J Kid Dis, 34:889–893, 1999; Kosch et al.,
Nephrol Dial Transplant, 15:1710–1711, 2000; Oymak
et al., Nephron, 86:346–347, 2000; Chun et al., Am J
Nephrol, 20:344–346, 2000; Chung et al., Am J Nephrol,
22:397–401, 2002; Asaba et al., Clin Exp Nephrol,
7:296–300, 2003; Haraguchi et al., Clin Exp Nephrol,
10:74–77, 2006; Saigusa et al., J Nephrol, 19:656–658,
2006; Okuyama et al., Clin Nephrol, 6:412–415, 2007;
Nishi et al., Clin Nephrol, 5:393–398, 2010; Ulusoy et al.,
Intern Med, 49:2477, 2010). A review of previous reports
of renal biopsy cases with MPN in the English literature
suggested that circulation control is important for the
treatment of renal disorders that mimic glomerulonephritis
in MPN.
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Introduction
Although several cases of glomerulonephritis with myelo-
proliferative neoplams (MPN) such as polycythemia vera
(PV) or essential thrombocythemia (ET) have been repor-
ted, the association between MPN and glomerulonephritis
is still obscure. The purpose of this article was to evaluate
whether MPN can cause glomerulonephritis.
We describe three MPN cases in which renal biopsies
were performed. Paraffin sections from the biopsied spec-
imens of the three cases were examined with hematoxylin
and eosin, periodic acid-Schiff, methenamine silver, and
Masson’s trichrome stains. Immunoglobulins (IgG, IgA,
and IgM), complement (C3 and C1q), and fibrinogen were
assessed by a direct immunofluorescence staining method
on frozen sections for two cases and by immunostaining on
paraffin sections for the other case. Electron microscopy
was performed for all three cases.
Here, we also review previously reported cases in the
English literature of renal glomerular disorders associated
with MPN, which were examined by renal biopsy.
Case reports
Case 1
A 76-year-old woman with a history of bronchial asthma
complained of edema. She had been diagnosed with
thrombocytosis due to ET 3 years earlier. Her condition
was stable at diagnosis, but edema occurred 2 months later,
upon which administration of hydroxyurea was initiated.
The patient’s height, weight, and blood pressure were
150 cm, 50 kg, and 180/80 mmHg, respectively. She was
alert and appeared healthy. She did not have any
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remarkable heart, lung, or abdominal abnormalities. Pitting
edema was demonstrated in her lower extremity.
The laboratory data were as follows: hemoglobin,
15.8 g/dl; hematocrit, 47.3 %; platelets, 490,000/ll; white
blood cells, 8,100/ll, C-reactive protein,\0.2 mg/dl; blood
urea nitrogen, 25.7 mg/dl; serum creatinine, 1.2 mg/dl;
total cholesterol, 182 mg/dl; total protein, 5.9 g/dl; albu-
min, 3.1 g/dl; globulin, 2.8 g/dl; lactate dehydrogenase,
241 IU/l; aspartate aminotransferase, 18 IU/l; alanine
aminotransferase, 12 IU/l; total bilirubin, 0.3 mg/dl;
c-glutamyl transpeptidase, 25 IU/l; alkaline phosphatase,
284 IU/l; Na, 141 mmol/l; K, 4.8 mmol/l; and Cl,
109 mmol/l. Urinalysis showed 3? proteinuria and 2?
hematuria.
Renal biopsy was performed (Fig. 1); 13 glomeruli could
be evaluated, 2 of which exhibited global sclerosis. Mod-
erate mesangial proliferation with several crescents and
arteriolosclerotic changes were observed. Immunohistological
staining was positive for IgG and IgA with a granular pattern
and negative for IgM, C1q, C3, and fibrinogen. Electron
microscopy showed electron-dense deposits in the mesan-
gium. The patient was diagnosed with IgA nephropathy with
an active lesion, and treatment consisting of 30 mg pred-
nisolone, 50 mg cyclophosphamide, and 80 mg telmisartan
per day was started. Although treatment improved the pro-
teinuria and hematuria, the patient’s serum creatinine level
remained unchanged. Telmisartan decreased her blood
pressure, but her hematocrit level could not be normalized.
The patient experienced a complicated acute myocardial
infarction 3 years later. She died 5 years later from ischemic
bowel disorder and heart failure.
Case 2
A 62-year-old woman was admitted to our hospital because
of general fatigue and chest discomfort. She had experi-
enced acute glomerulonephritis 6 years previously, but the
details of the clinical course were not known. Proteinuria
had been detected while she was pregnant, and she had
been treated for hypertension for 15 years. She had been
diagnosed with ET at another hospital 3 years earlier. No
remarkable cardiac problems were found when she was
examined at the Department of Cardiology after admission.
She was referred to the Department of General Medicine
for a renal biopsy to investigate the persistent proteinuria.
The patient’s height, weight, and blood pressure were
148 cm, 55 kg, and 179/107 mmHg, respectively. Her
consciousness level was alert and she looked well. A sys-
tolic murmur was detected at the 4 left sternal border. She
did not have remarkable abnormalities in the lungs and
abdomen and did not show pitting edema.
The laboratory data were as follows: hemoglobin,
11.4 g/dl; hematocrit, 39.8 %; platelets, 978,000/ll; white
blood cells, 14,400/ll; C-reactive protein, \0.2 mg/dl;
blood urea nitrogen, 15.8 mg/dl; serum creatinine, 0.7 mg/
dl; total cholesterol, 227 mg/dl; total protein, 7.3 g/dl;
albumin, 4.5 g/dl; globulin, 2.8 g/dl; lactate dehydroge-
nase, 811 IU/l; aspartate aminotransferase, 22 IU/l; alanine
aminotransferase, 11 IU/l; total bilirubin, 0.3 mg/dl;
c-glutamyl transpeptidase, 21 IU/l; alkaline phosphatase,
470 IU/l; Na, 144 mmol/l; K, 5.0 mmol/l; and Cl,
107 mmol/l. Urinalysis showed 4? proteinuria (1.51 g/day)
and no evidence of hematuria.
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in the mesangial region of a
glomerulus identified by
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dense deposits in the mesangial
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Renal biopsy was performed (Fig. 2), and 19 glomeruli
could be evaluated, 2 of which exhibited global sclerosis.
The histological findings included mild glomerular changes
with arteriolosclerotic changes. Immunofluorescence
staining was positive for IgM and weakly positive for IgA.
Electron microscopy did not show any obvious electron-
dense deposits. She was treated with felodipine, an anti-
hypertensive, as well as antiplatelet drugs. The control of
her blood pressure was slightly poor. Her renal function
remained stable, but the proteinuria persisted.
Case 3
A 51-year-old man was admitted to our hospital for renal
biopsy. Proteinuria had been detected when the patient was
approximately 30 years of age, and he had experienced
tonsillitis several times. The patient had been diagnosed
with PV with an abnormality of the JAK2 gene 3 years
earlier. Renal biopsy was planned because his proteinuria
had become more apparent over the past 2 years.
The patient’s height, weight, and blood pressure were
165 cm, 66 kg, and 120/73 mmHg, respectively. His con-
sciousness level was alert, and he appeared healthy. No
remarkable abnormalities were found in the heart, lungs, or
abdomen, and pitting edema was not observed.
The laboratory data were as follows: hemoglobin,
15.3 g/dl; hematocrit, 48.1 %; platelets, 326,000/ll; white
blood cells, 8,400/ll; C-reactive protein,\0.2 mg/dl; blood
urea nitrogen, 22.2 mg/dl; serum creatinine, 1.4 mg/dl;
total cholesterol, 194 mg/dl; total protein, 7.1 g/dl; albu-
min, 4.1 g/dl; globulin, 3.0 g/dl; lactate dehydrogenase,
169 IU/l; aspartate aminotransferase, 17 IU/l; alanine
aminotransferase, 23 IU/l; total bilirubin, 0.5 mg/dl;
c-glutamyl transpeptidase, 21 IU/l; alkaline phosphatase,
276 IU/l; Na, 139 mmol/l; K, 4.7 mmol/l; and Cl,
106 mmol/l. Urinalysis showed 4? proteinuria (1.2 g/day)
and no evidence of hematuria.
Renal biopsy was performed (Fig. 3) and 22 glomeruli
could be evaluated, 5 of which showed global sclerosis.
Histological findings included mesangial proliferative
glomerulonephritis with crescents and focal segmental
necrosis. Arteriosclerotic changes were also observed.
Immunofluorescence staining was positive and revealed
strong immunoreactivity for IgA and C3. Electron
microscopy showed electron-dense deposits in the mesan-
gium. He was diagnosed with IgA nephropathy. Tonsil-
lectomy plus steroid pulse therapy and an angiotensin II
receptor blocker were selected as treatments for the patient.
His proteinuria and hematuria disappeared after 6 months.
Discussion
According to the World Health Organization classification,
MPNs are classified into the following six diseases: PV,
ET, chronic myelogenous leukemia (CML), primary mye-
lofibrosis (PMF), chronic neutrophilic leukemia (CNL),
and chronic eosinophilic leukemia/hypereosinophilic syn-
drome (CEL/HES) [16]. Most reports of glomerular disease
associated with MPN have involved PV or ET, whereas
few reports have described associations with PMF, CML,
CNL, or CEL/HES. We limited our subjects to cases with
Fig. 2 Case 2. a Micrograph of
the glomeruli showing
mesangial proliferation.
b Interlobular artery with
intimal thickening.
c Immunoglobulin M deposition
in the mesangial region of a
glomerulus identified by
immunostaining
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PV or ET in this study and found 21 appropriate cases in
the English literature between 1980 and 2010 [1–15].
The 21 cases in the literature and our 3 cases are shown
in Table 1 [1–15].
The average patient age of these 24 cases (16 men and 8
women) was 55.1 years. PV was found in 17 patients and
ET in 7 patients. Of the 24 cases, 5 cases, including 2 of
ours, were diagnosed with IgA nephropathy (IgAN) after
renal biopsy: focal segmental glomerulosclerosis (FSGS) in
10 cases, membranous glomerulonephritis in 1 case,
membranoproliferative glomerulonephritis in 1 case, pur-
pura nephritis in 1 case, and fibrillary glomerulonephritis in
1 case. The other 5 cases were not specified. Hypertension
was observed in 20 of 24 cases. Treatments consisted of
antihypertensive drugs for 13 patients, phlebotomy for 12
patients, corticosteroid for 8 patients, hydroxycarbamide
for 8 patients, and cyclophosphamide for 4 patients. Uri-
nalysis improvement was seen in 13 cases, 9 of which were
treated with antihypertensive agents, 7 with phlebotomy,
and 6 with corticosteroid. Four cases worsened despite
treatment.
Cases of glomerular disease associated with MPN have
been reported occasionally. Although Au et al. [5] detected
5 cases of FSGS (3.6 %) among 138 patients with MPN,
the frequency of glomerular disorders among MPN patients
is unknown. Therefore, reports that various types of glo-
merular disease are associated with MPN indicate that the
pathogenesis of this condition is complex. Au et al. sug-
gested that high platelet counts and abnormal activation of
megakaryocytes are predisposing factors for glomerulo-
sclerosis and that aggressive treatment to lower the platelet
count can prevent the development of renal abnormalities
[5]. On the other hand, antihypertensive agents, such as an
angiotensin II receptor blocker (ARB), were selected for
treatment because of complication of hypertension. Ulusoy
reported the successful treatment of 1 case with antihy-
pertensive drug administration and phlebotomy [15]. A
good response after phlebotomy was observed in 2 cases
[3, 6]. MPN, especially PV and ET, are susceptible to
complication by thrombosis or hypertension [17]. Alter-
nation of renal hemodynamics in patients with MPN might
cause glomerular endothelial injury. Endothelial cell
damage could induce activation of platelets and release of
cytokines such as PDGF (platelet-derived growth factor).
Floege et al. [18] suggested that PDGF might mediate
glomerular injury and cause exacerbation of glomerulone-
phritis. They clarified that PDGF could induce mesan-
gial and endothelial cell proliferation. Other candidate
Fig. 3 Case 3. a Micrograph of
the glomeruli showing
mesangial proliferation.
b Micrograph of the glomeruli
showing a fibrocellular crescent
formation. c Immunoglobulin A
deposition in the mesangial
region of a glomerulus
identified by immunostaining.
d Electron-dense deposits in the
paramesangial region
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cytokines such as insulin-like growth factor-1, platelet-
activating factor, transforming growth factor-b, and
plasmalemmal vesicle-associated protein-1 had been
reported to play a role in the pathogenesis of glomerulo-
nephritis in MPN patients, though a definite role for these
factors has not been established [2, 4, 5, 14]. Sharma et al.
[2] and Kosch et al. [6] reported that improvement of
hematocrit levels might be useful for reducing protein urea
and recovering renal function. Controlling renal hemody-
namics and blood cell proliferation might be important for
improving renal disease in MPN patients. Unfortunately,
with regard to our cases, the effectiveness of these treat-
ments could not be clarified.
Regarding the clinical course, glomerulonephritis was
thought to have preceded MPN in 2 of our cases (cases 2
and 3). In case 1, a case of IgA nephropathy, the onset of
IgA nephropathy did not occur until 2 years after the PV
diagnosis. Although the documented onset of MPN pre-
ceded renal disease in 9 of the 21 previously reported
cases, a period of 10 years or more passed between the
onset of MPN and that of renal disease in 3 cases, indi-
cating that an association between MPN and the onset of
renal disease is unlikely. In those cases, glomerular dis-
eases were considered to simply overlap with MPN.
However, MPN might exacerbate glomerular disease
because of the alternation of renal hemodynamics at least
in part.
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